SEARCH

SEARCH BY CITATION

References

  • Adjorlolo-Johnson G, Unger ER, Boni-Ouattara E et al. (2010) Assessing the relationship between HIV infection and cervical cancer in Cote d’Ivoire: a case–control study. BMC Infectious Diseases10, 242.
  • Aral SO (1999) Sexual network patterns as determinants of STD rates: paradigm shift in the behavioral epidemiology of STDs made visible. Sexually Transmitted Diseases26, 262264.
  • Ault KA (2007) Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecologic Oncology107, S31S33.
  • Banura C, Mirembe FM, Katahoire AR et al. (2011) Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: a systematic review. Infectious Agents and Cancer6, 11.
  • Bosch FX, Manos MM, Muñoz N et al. (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. Journal of the National Cancer Institute87, 796802.
  • Bruni L, Diaz M, Castellsagué X et al. (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. Journal of Infectious Diseases202, 17891799.
  • Burchell AN, Winer RL, de Sanjosé S et al. (2006) Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine24 (Suppl. 3), S3/5261.
  • Castellsagué X, Klaustermeier J, Carrilho C et al. (2008) Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention. International Journal of Cancer122, 19011904.
  • Cates W Jr (1999) Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sexually Transmitted Diseases26, S2S7.
  • Centers for Disease Control and Prevention (1993) Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The Journal of the American Medical Association269, 729730.
  • de Sanjosé S, Quint WG, Alemany L et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The Lancet Oncology11, 10481056.
  • De Vuyst H, Lillo F, Broutet N et al. (2008) HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. European Journal of Cancer Prevention17, 545554.
  • De Vuyst H, Clifford GM, Nascimento MC et al. (2009) Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. International Journal of Cancer124, 16261636.
  • De Vuyst H, Gathari N, Manivasan M et al. (2012) Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. International Journal of Cancer131, 949955.
  • Einstein MH, Baron M, Levin MJ et al. (2011) Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years. Human Vaccines and Immunotherapeutics7, 13591373.
  • Ferlay J, Shin H-R, Bray F et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Internatinal Journal of Cancer127, 28932917.
  • GAVI Alliance (2012) New and underused vaccines support. http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccine-support/ .
  • Hawes SE, Critchlow CW, Faye Niang MA et al. (2003) Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. Journal of Infecious Diseases188, 555563.
  • Keita N, Clifford GM, Koulibaly M et al. (2009) HPV infection in women with and without cervical cancer in Conakry, Guinea. British Journal of Cancer101, 202208.
  • Koutsky L (1997) Epidemiology of genital human papillomavirus infection. American Journal of Medicine102, 38.
  • Merck (2012) Broad spectrum HPV (human papillomavirus) vaccine study in 16- to 26-year-old women (V503–001). http://clinicaltrials.gov/show/NCT00543543. Accessed June 2012.
  • Muñoz N, Bosch FX, de Sanjose S et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. The New England Journal of Medicine348, 518527.
  • Naucler P, Da Costa FM, Ljungberg O et al. (2004) Human papillomavirus genotypes in cervical cancers in Mozambique. Journal of General Virology85 (Pt 8), 21892190.
  • Odida M, de Sanjose S, Quint WG et al. (2008) Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infectious Diseases8, 85.
  • Pirog EC, Kleter B, Olgac S et al. (2000) Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. American Journal of Pathology157, 10551062.
  • Roberts C, Brownlow MK, Smith JF et al. (2011) HPV6, 11, 16, and 18 Immunogenicity of four multi-valent HPV vaccine formulations in non-human primates. Abstract book. 27th International Papillomavirus Conference and Clinical Workshop, Berlin, Germany.
  • Trottier H, Mahmud S, Costa MC et al. (2006) Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiology, Biomarkers & Prevention15, 12741280.
  • UNAIDS (2009) AIDS epidemic update, 2009 Estimates. http://www.unaids.org/en/regionscountries/ .
  • Walboomers JM, Jacobs MV, Manos MM et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology189, 1219.
  • WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) (2010) Human papillomavirus and related cancers in Senegal. Summary report update. http://www.who.int/hpvcentre .
  • World Health Surveys (2003) Household Surveys with Geographical Information System (GIS) Multistage Cluster Sampling. Screening Coverage among Women Aged 18–69. WHO, Geneva.